ANTIPSYCHOTIC MEDICATION INFLUENCES THE DISCRIMINATIVE VALUE OF ACYLETHANOLAMIDES AS BIOMARKERS OF SUBSTANCE USE DISORDER

Grupo de Neuropsicofarmacología, IBIMA-Plataforma BIONAND, Hospital Regional Universitario de Málaga, Universidad de Málaga

The study investigates the role of acylethanolamides as potential biomarkers in patients with substance use disorders (SUD) and how these levels are influenced by antipsychotic medications. It highlights the complexity of the interaction between the endocannabinoid system and psychiatric treatment, suggesting that medication may modulate biomarker levels, thereby impacting diagnosis and treatment strategies. The research emphasizes the need for further exploration into the adaptive responses of these biomarkers in relation to drug consumption and underlying psychiatric conditions.